Skip to main content
Premium Trial:

Request an Annual Quote

Digene to Distribute Asuragen s CF Screening Products Worldwide

NEW YORK, April 19 (GenomeWeb News) - Digene will market and distribute cystic fibrosis screening products made by Asuragen, the newly formed molecular diagnostic company spun out of Ambion, the partners said today.

 

Terms of the exclusive, worldwide deal call for Digene to make an up-front payment to Asuragen, and to make additional payments based on regulatory milestones.

 

Asuragen will also develop its next-generation CF test, Signature CF Expand, which will broaden the mutation panel to include ethnic-specific mutations that can be adapted for use in carrier screening and may find additional utility for neonatal and newborn testing. Digene will also distribute this product exclusively and worldwide.

 

In addition, Digene will have the first right of refusal on future genetic test products developed by Asuragen. The Signature products use the Luminex xMAP technology.

 

Asuragen was formed after Applied Biosystems  acquired Ambion's RNA business in March.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.